| Literature DB >> 23860346 |
Carrie N Moseley1, Heather A Simpson-Khanna, Glenn Catalano, Maria C Catalano.
Abstract
The atypical antipsychotic agents are felt by many to have a lower risk of inducing the development of dyskinetic movements than the conventional antipsychotic agents agents such as haloperidol and fluphenazine. However, that does not mean that treatment with the atypical antipsychotic agents carries no risk of developing dyskinesias. To the contrary, all of the atypical antipsychotic agents, including aripiprazole, have been associated with the induction of dyskinetic movements. We will present the case of a patient who developed a covert dyskinesia that manifested shortly after the discontinuation of aripiprazole. We will review the use of aripiprazole and the adverse effects most commonly associated with its use. We will also discuss the risk factors associated with the development of tardive dyskinesia and review the different clinical variations (withdrawal dyskinesia, covert dyskinesia, tardive diskinesia) of medication-induced dyskinesias.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23860346 DOI: 10.1097/WNF.0b013e31829b99d9
Source DB: PubMed Journal: Clin Neuropharmacol ISSN: 0362-5664 Impact factor: 1.592